Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)
Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)
Patients with an acute exacerbation of Relapsing-Remitting Multiple Sclerosis or with
 Clinically Isolated Syndrome receive either one single infusion of Nanocort or three daily
 infusions of SoluMedrol. Main objective is to assess the occurrence of new
 gadolinium-enhanced T1-weighted lesions at week 8 vs week 1 after treatment.
INCLUSION criteria

 -  Diagnosis of RRMS (per McDonald criteria, 2005) with dissemination in time and space
 OR a diagnosis of CIS confirmed by MRI. Patients with CIS who only have optic neuritis
 will be excluded from this study

 -  A maximum Expanded Disability Status Scale (EDSS) score of ≤ 6

 -  New neurological symptoms or exacerbation of prior neurological symptoms of over 24
 hours duration but <7 days duration, verified by neurological examination

 EXCLUSION criteria:

 -  Primary progressive MS.

 -  Secondary progressive MS without superimposed relapses.

 -  Received systemic corticosteroids within 4 weeks of screening for treatment of MS or
 other conditions.

 -  any contraindication for treatment with (systemic) corticosteroids